C-J Advisory’s Amgen AMGN Stock Holding History

C-J Advisory’s Portfolio AMGN Stock Details AMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-208	Closed	-$40K	–	48
2019 Q3	$40K	Hold	208	–	–	0.03%	56
2019 Q2	$38K	Hold	208	–	–	0.02%	56
2019 Q1	$40K	Hold	208	–	–	0.03%	57
2018 Q4	$40K	Hold	208	–	–	0.03%	50
2018 Q3	$43K	Hold	208	–	–	0.03%	51
2018 Q2	$38K	Sell	208 -60	-22%	-$10.6K	0.03%	54
2018 Q1	$45K	Hold	268	–	–	0.03%	50
2017 Q4	$47K	Buy	+268	New	+$47.4K	0.03%	43

Other funds holding AMGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

C-J Advisory's AMGN Position: Q4 2019 in Review

C-J Advisory sold out of Amgen (AMGN) in Q4 2019, closing a stake of 208 shares — an estimated $40K sold.

C-J Advisory first reported a position in AMGN in Q4 2017 and held it in 8 quarters. The position peaked at $47K in Q4 2017. 2,107 funds tracked by Wall St. Rank hold AMGN as of Q4 2019.

C-J Advisory reported no remaining Amgen position as of Q4 2019 after selling out during the quarter.
C-J Advisory sold 208 Amgen shares in Q4 2019, an estimated $40K.
C-J Advisory first reported a position in Amgen in Q4 2017 and held it in 8 quarters.
C-J Advisory's Amgen position peaked at $47K in Q4 2017.
2,107 funds tracked by Wall St. Rank held Amgen as of Q4 2019.

Based on C-J Advisory's 13F filing for Q4 2019, filed 10 Feb 2020.